
AI Drug Startup Chai Discovery Lands Lilly Deal
Chai Discovery, an AI startup founded in 2024, is rapidly gaining prominence in AI-driven drug discovery, securing significant funding and a partnership with Eli Lilly to accelerate antibody development using its Chai-2 algorithm. This collaboration, alongside Eli Lilly's $1 billion investment with Nvidia in an AI drug discovery lab, highlights the increasing importance of AI and machine learning in revolutionizing pharmaceutical research and development, potentially leading to faster and more efficient creation of new medicines.



















Discussion
Join the conversation
Be the first to comment